Sirnaomics is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Maryland, United States, with branches in Boston (USA), Hong Kong, Guangzhou, and Suzhou in China.

Sirnaomics is the first to achieve positive Phase IIb clinical outcomes in oncology clinical-stage RNA therapeutics. It is a biopharmaceutical company with a strong presence in both Asia and the U.S. that is discovering and developing innovative drugs for significant unmet medical needs and large market opportunities. They have built a professional international team for the discovery and development of RNAi therapeutics and mRNA vaccines and therapeutics, based on their proprietary drug delivery technology platforms.

Sirnaomics was listed on the Hong Kong Stock Exchange at the end of 2024. Its clinical pipeline of small interfering RNA (siRNA) therapeutics primarily focuses on oncology. The company possesses unique patented technologies for targeted drug delivery into the nuclei of tumor cells, enabling precision treatment. Its representative drug candidates, STP705 and STP707, are both currently in Phase II clinical trials.